Pfizer drug fails in two Phase III lung cancer studies

Pfizer said its experimental drug dacomitinib failed in two Phase III studies of patients with advanced lung cancer.

Pfizer said its experimental drug dacomitinib failed in two Phase III studies of patients with advanced lung cancer.

The studies tested the drug in previously treated patients with non-small cell lung cancer. The drug didn’t show an overall...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category